Literature DB >> 31598983

Changes in total lymphocyte count and neutrophil-to-lymphocyte ratio after curative pancreatectomy in patients with pancreas adenocarcinoma and their prognostic role.

Eun Y Kim1, Tae H Hong2.   

Abstract

BACKGROUND AND OBJECTIVES: To assess the prognostic significance of postoperative changes in immune status represented by total lymphocyte count (TLC) and neutrophil-to-lymphocyte ratio (NLR) in resectable pancreatic cancer.
METHODS: Patients who underwent curative pancreatectomy for pancreatic adenocarcinoma were divided into high and low groups according to cut-off values of TLC, and NLR measured preoperatively, immediately after surgery, and 1 or 6 months after surgery. Oncologic outcomes were compared between the two groups at different times, and prognostic roles of TLC and NLR were evaluated.
RESULTS: Of 193 patients, the median follow-up time was 22 months, and median survival was 18 months. Their immunologic status deteriorated within 3 to 4 days after the operation and recovered after that. At 1 and 6 months postoperatively, overall survival rates were significantly lower in the group with high NLR (>2.535 and >3.21, respectively) and low TLC (<1.66 × 109 and <1.62 × 109 /L, respectively). In multiple regression analyses, elevated NLR at postoperative 1 and 6 months and decreased TLC at postoperative 1 month were significant prognosis predictors.
CONCLUSIONS: Changes in immune status such as decreased TLC and elevated NLR at postoperative 1 and 6 months are effective prognostic predictors after curative pancreatectomy in patients with pancreatic adenocarcinoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  lymphocyte count; neutrophil-to-lymphocyte ratio; pancreatectomy; pancreatic ductal carcinomas

Mesh:

Year:  2019        PMID: 31598983     DOI: 10.1002/jso.25725

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study.

Authors:  Ziyao Wang; Nengwen Ke; Xin Wang; Xing Wang; Yonghua Chen; Hongyu Chen; Jinheng Liu; Du He; Bole Tian; Ang Li; Weiming Hu; Kezhou Li; Xubao Liu
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

Review 2.  Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies.

Authors:  Fan Tang; Yan Tie; Chongqi Tu; Xiawei Wei
Journal:  Clin Transl Med       Date:  2020-01

3.  The role of systemic immuno-inflammatory factors in resectable pancreatic adenocarcinoma: a cohort retrospective study.

Authors:  D Schlanger; C Popa; S Pașca; A Seicean; N Al Hajjar
Journal:  World J Surg Oncol       Date:  2022-05-06       Impact factor: 3.253

4.  Combined prognostic nutritional index ratio and serum amylase level during the early postoperative period predicts pancreatic fistula following pancreaticoduodenectomy.

Authors:  Teruhisa Sakamoto; Takuki Yagyu; Ei Uchinaka; Masaki Morimoto; Takehiko Hanaki; Joji Watanabe; Manabu Yamamoto; Tomoyuki Matsunaga; Naruo Tokuyasu; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  BMC Surg       Date:  2020-08-06       Impact factor: 2.102

5.  Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.

Authors:  Chirayu Mohindroo; Merve Hasanov; Jane E Rogers; Wenli Dong; Laura R Prakash; Seyda Baydogan; Jonathan D Mizrahi; Michael J Overman; Gauri R Varadhachary; Robert A Wolff; Milind M Javle; David R Fogelman; Michael T Lotze; Michael P Kim; Matthew H G Katz; Shubham Pant; Ching-Wei D Tzeng; Florencia McAllister
Journal:  Cancer Med       Date:  2021-07-11       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.